AvailOm is the company’s proprietary method of combining high concentration omega-3 fish oils with lysine salts to boost absorpotion. The company claims a study published in December in the journal Prostaglandins, Leukotrienes and Essential Fatty Acids validates the claims for better absorption as well as better stability.
The new ingredients that have been approved by ANVISA, the Brazilian food and drug regulatory agency, are AvailOm® 50 High EPA and AvailOm® 50 High DHA.
In addition to the higher bioavailability, the AvailOm platform is formulated as a powder. This means it can be compressed into tablets and will allow additonal ingredients, such as botanicals, to easily be added.
“Evonik’s omega-3 lysine complex solves many challenges in the development of highly concentrated and yet convenient food supplements, addressing the needs of various consumer groups, such as pregnant women, mothers, and healthy agers,” said Dr Christopher Studte, Director New Health Ingredients at Evonik Health Care.
Evonik also offers an algae-oil derived form the of AvailOm ingredients. That form was not part of the Brazilian market application.
Other moves in health, wellness space
This latest development is part of a number of moves Evonik has been making in the health, wellness and personal care spaces. In January of 2020 the company announced a deal to acquire private US firm Wilshire Technologies. The deal brought on board the capability to use plant derived phytochemicals in topical applications.
Evonik also concluded a research collaboration deal with the University of California San Diego centered on new studies into the microbiome. The UCSD research effort is led by renonwed microbiome expert Rob Knight, PhD. Knight’s Center for Microbiome Innovation has assembled a research team that now includes more than 140 allied UCSD faculty. Evonik is partnering on a project to develop a model for the skin microbiome.